MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...

PacBio announced its involvement in a groundbreaking study published in Nature Genetics, which utilized its advanced sequencing technology to explore the genetic basis of a rare Mendelian condition in ...

PacBio announced the early shipment of its Vega benchtop sequencing system and the launch of SPRQ chemistry, enabling affordable HiFi genome sequencing for under $500 on the Revio system. Despite ...

MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for ...

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide ALS is a progressive neurodegenerative ...

PacBio (PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics ...

“We’ve seen tremendous demand for Revio systems over the last two years as many more researchers have discovered the superiority of HiFi technology in population sequencing and other human and ...

MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...

The National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate genomic and epigenomic data from as many as 7,800 participants. The effort will rely on PacBio’s ...

Pacific Biosciences of California, Inc. is downgraded to Hold with slow commercial adoption & academic funding pressures.